Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Runx2-Smad signaling impacts the progression of tumor-induced bone disease.

Zhang X, Akech J, Browne G, Russell S, Wixted JJ, Stein JL, Stein GS, Lian JB.

Int J Cancer. 2015 Mar 15;136(6):1321-32. doi: 10.1002/ijc.29094. Epub 2014 Aug 5.

2.

Expression of the IL-11 Gene in Metastatic Cells Is Supported by Runx2-Smad and Runx2-cJun Complexes Induced by TGFβ1.

Zhang X, Wu H, Dobson JR, Browne G, Hong D, Akech J, Languino LR, Stein GS, Lian JB.

J Cell Biochem. 2015 Sep;116(9):2098-108. doi: 10.1002/jcb.25167.

3.

Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB.

Oncogene. 2010 Feb 11;29(6):811-21. doi: 10.1038/onc.2009.389. Epub 2009 Nov 16.

5.

The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.

van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, Languino LR, Lian JB, van Wijnen AJ, Stein JL, Stein GS.

J Cell Biochem. 2010 Mar 1;109(4):828-37. doi: 10.1002/jcb.22463.

6.

Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal.

Javed A, Bae JS, Afzal F, Gutierrez S, Pratap J, Zaidi SK, Lou Y, van Wijnen AJ, Stein JL, Stein GS, Lian JB.

J Biol Chem. 2008 Mar 28;283(13):8412-22. doi: 10.1074/jbc.M705578200. Epub 2008 Jan 18.

7.

Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.

Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B.

Mol Cancer. 2010 Sep 23;9:258. doi: 10.1186/1476-4598-9-258.

8.

Specific residues of RUNX2 are obligatory for formation of BMP2-induced RUNX2-SMAD complex to promote osteoblast differentiation.

Javed A, Afzal F, Bae JS, Gutierrez S, Zaidi K, Pratap J, van Wijnen AJ, Stein JL, Stein GS, Lian JB.

Cells Tissues Organs. 2009;189(1-4):133-7. doi: 10.1159/000151719. Epub 2008 Aug 26.

9.

Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells.

Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB.

Cancer Res. 2008 Oct 1;68(19):7795-802. doi: 10.1158/0008-5472.CAN-08-1078.

10.

Smad-Runx interactions during chondrocyte maturation.

Leboy P, Grasso-Knight G, D'Angelo M, Volk SW, Lian JV, Drissi H, Stein GS, Adams SL.

J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 1):S15-22. Review.

PMID:
11263661
11.

Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway.

Ye L, Kynaston H, Jiang WG.

J Urol. 2009 Jun;181(6):2749-59. doi: 10.1016/j.juro.2009.01.098. Epub 2009 Apr 17.

PMID:
19375725
12.

Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.

Mendoza-Villanueva D, Zeef L, Shore P.

Breast Cancer Res. 2011 Oct 27;13(5):R106. doi: 10.1186/bcr3048.

13.

Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription.

Afzal F, Pratap J, Ito K, Ito Y, Stein JL, van Wijnen AJ, Stein GS, Lian JB, Javed A.

J Cell Physiol. 2005 Jul;204(1):63-72.

PMID:
15573378
14.

Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone.

Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS.

Cancer Metastasis Rev. 2006 Dec;25(4):589-600. Review.

PMID:
17165130
15.

A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.

Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA.

J Transl Med. 2011 Oct 28;9:185. doi: 10.1186/1479-5876-9-185.

16.

Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.

Dey P, Jonsson P, Hartman J, Williams C, Ström A, Gustafsson JÅ.

Mol Endocrinol. 2012 Dec;26(12):1991-2003. doi: 10.1210/me.2012.1227. Epub 2012 Oct 1.

17.

Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Virk MS, Alaee F, Petrigliano FA, Sugiyama O, Chatziioannou AF, Stout D, Dougall WC, Lieberman JR.

Bone. 2011 Mar 1;48(3):578-87. doi: 10.1016/j.bone.2010.11.003. Epub 2010 Nov 10.

18.

TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction.

Yuen HF, Kwok WK, Chan KK, Chua CW, Chan YP, Chu YY, Wong YC, Wang X, Chan KW.

Carcinogenesis. 2008 Aug;29(8):1509-18. doi: 10.1093/carcin/bgn105. Epub 2008 May 2.

PMID:
18453541
19.

The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion.

Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB.

Mol Cell Biol. 2005 Oct;25(19):8581-91.

20.

BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype.

Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT.

J Bone Miner Res. 2006 Apr;21(4):637-46. Epub 2006 Apr 5.

Supplemental Content

Support Center